Progressive multifocal leukoencephalopathy

Current Treatment Options in Neurology

Volumn 2, Issue 4, 2000, Pages 361-368

  Berger, Joseph R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cidofovir; Cytosine Arabinoside; Main Drug Interaction; Progressive Multifocal Leuko; Progressive Multifocal Leukoencephalopathy

Indexed keywords

EID: 0000696698     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-000-0053-7     Document Type: Article

References (54)

1. Astrom K, Mancall E, Richardson E: Progressive multifocal leukoencephalopathy. Brain 1958, 81:93–111. This is a seminal paper in which PML was first clearly described and recognized as a unique illness.
2. Zu Rhein G, Chou S: Particles resembling papovaviruses in human cerebral demyelinating disease. Science 1965, 148:1477–1479.
3. Padgett B, Walker DL, ZuRhein GM, et al.: Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971, 1:1257–1260.
4. Monaco MC, Jensen PN, Hou J, et al.: Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 1998, 72(12):9918–9923.
5. Holman RC, Janssen RS, Buehler JW, et al.: Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 1991, 41(11):1733–1736.
6. Moret H, Guichard M, Matheron S, et al.: Virological diagnosis of progressive multifocal leukoencephalopathy: detection of JC virus DNA in cerebrospinal fluid and brain tissue of AIDS patients. J Clin Microbiol 1993, 31(12):3310–3313.
7. Brooks BR, Walker DL: Progressive multifocal leukoencephalopathy. Neurol Clin 1984, 2(2):299–313. A very good review of PML in the era preceding AIDS.
8. Whiteman ML, Post MJ, Berger JR, et al.: Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 1993, 187(1):233–240.
9. Berger JR, Pall L, Lanska D, Whiteman M: Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998, 4(1):59–68. The largest series of patients with PML ever collected is reported in this paper. The clinical and radiographic features in the AIDS population are described in detail.
10. Houff SA, Major EO, Katz DA, et al.: Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988, 318(5):301–305.
11. Berger J, Major E: Progressive multifocal leukoencephalopathy. In Textbook of AIDS Medicine. Edited by Merigan T, Barlett J, Bolognesi D. Baltimore: Williams & Wilkins; 1999:403–420. An excellent review of JC virus and PML in general.
12. Dorries K, Arendt G, Eggers C, et al.: Nucleic acid detection as a diagnostic tool in polyomavirus JC induced progressive multifocal leukoencephalopathy. J Med Virol 1998, 54(3):196–203.
13. Cinque P, Vago L, Dahl H, et al.: Polymerase chain reaction on cerebrospinal fluid for diagnosis of virusassociated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS 1996, 10(9):951–958.
14. Tachikawa N, Goto M, Hoshino Y, et al.: Detection of Toxoplasma gondii, Epstein-Barr virus, and JC virus DNAs in the cerebrospinal fluid in acquired immunodeficiency syndrome patients with focal central nervous system complications. Intern Med 1999, 38(7):556–562.
15. Weber T, Klapper PE, Cleator GM, et al.: Polymerase chain reaction for detection of JC virus DNA in cerebrospinal fluid: a quality control study. European Union Concerted Action on Viral Meningitis and Encephalitis. J Virol Methods 1997, 69(1-2):231–237.
16. Hammarin AL, Bogdanovic G, Svedhem V, et al.: Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy. J Clin Microbiol 1996, 34(12):2929–2932.
17. Berger JR, Kaszovitz B, Post MJ, Dickinson G: Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 1987, 107(1):78–87.
18. von Einsiedel RW, Fife TD, Aksamit AJ, et al.: Progressive multifocal leukoencephalopathy in AIDS: a clinicopathologic study and review of the literature. J Neurol 1993, 240(7):391–406.
19. Berger JR, Levy RM, Flomenhoft D, Dobbs M: Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998, 44(3):341–349.
20. Koralnik IJ, Boden D, Mai VX, et al.: JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999, 52(2):253–260.
21. Yiannoutsos CT, Major EO, Curfman B, et al.: Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 1999, 45(6):816–821.
22. Hall CD, Dafni U, Simpson D, et al.: Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998, 338(19):1345–1351. The only well-designed, controlled study of a pharmacologic intervention in PML, demonstrating that cytosine arabinoside is of no value as administered (either intravenously or intrathecally) in this study.
23. Berger JR, Mucke L: Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 1988, 38(7):1060–1065.
24. Goodman A, Gilman A: The Pharmacological Basis of Therapeutics, edn 7. New York: MacMillan Publishing Co.; 1985.
25. Hou J, Major E: The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 1998, 4(4):451–456.
26. Bauer WR, Turel AP, Johnson KP: Progressive multifocal leukoencephalopathy and cytarabine. Remission with treatment. JAMA 1973, 226(2):174–176.
27. Buckman R, Wiltshaw E: Progressive multifocal leucoencephalopathy successfully treated with cytosine arabinoside [letter]. Br J Haematol 1976, 34(1):153–158.
28. Conomy JP, Beard NS, Matsumoto H, Roessmann U: Cytarabine treatment of progressive multifocal leukoencephalopathy. Clinical course and detection of virus-like particles after antiviral chemotherapy. JAMA 1974, 229(10):1313–1316.
29. Lidman C, Lindqvist L, Mathiesen T, Grane P: Progressive multifocal leukoencephalopathy in AIDS [letter]. AIDS 1991, 5(8):1039–1041.
30. O’Riordan T, Daly PA, Hutchinson M, et al.: Progressive multifocal leukoencephalopathy—remission with cytarabine. J Infect 1990, 20(1):51–54.
31. Tashiro K, Dai S, Moriwaka F, et al.: Progressive multifocal leucoencephalopathy with magnetic resonance imaging verification and therapeutic trials with interferon. J Neurol 1987, 234(6):427–429.
32. Van Horn G, Bastian F, Moake J: Progressive multifocal leukoencephalopathy: failure of response to transfer factor and cytarabine. Neurology 1978, 28:794–797.
33. Andrei G, Snoeck R, Vandeputte M, DeClercq E: Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997, 41(3):587–593.
34. Sadler M, Chinn R, Healy J, et al.: New treatments for progressive multifocal leukoencephalopathy in HIV-1-infected patients [letter]. AIDS 1998, 12(5):533–535.
35. De Luca A, Fantoni M, Tartaglione T, Antinori A: Response to cidofovir after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 1999, 52(4):891–892.
36. Brambilla AM, Castagna N, Novati R, et al.: Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy [letter]. J Neurol 1999, 246(8):723–725.
37. Dodge RT: A case study: the use of cidofovir for the management of progressive multifocal leukoencephalopathy. J Assoc Nurses AIDS Care 1999, 10(4):70–74.
38. Blick G, Whiteside M, Griegor P, et al.: Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside. Clin Infect Dis 1998, 26(1):191–192.
39. Meylan PR, Vuadens P, Maeder P, et al.: Monitoring the response of AIDS-related progressive multifocal leukoencephalopathy to HAART and cidofovir by PCR for JC virus DNA in the CSF. Eur Neurol 1999, 41(3):172–174.
40. Steiger MJ, Tarnesby G, Gabe S, et al.: Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Ann Neurol 1993 33(4):407 411.
41. Berger J, Pall L, McArthur J, et al.: A pilot study of recombinant alpha 2a interferon in the treatment of AIDS-related progressive multifocal leukoencephalopathy [abstract]. Neurology 1992, 42(suppl 3):257.
42. Huang SS, Skolasky RL, DalPan GJ, et al.: Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J Neurovirol 1998, 4(3):324–332.
43. Rand KH, Johnson KP, Rubinstein LJ, et al.: Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: use of virus-containing cells in the urine to assess response to therapy. Ann Neurol 1977, 1(5):458–462.
44. Wolinsky JS, Johnson KP, Rand K, Merigan TC: Progressive multifocal leukoencephalopathy: clinical pathological correlates and failure of a drug trial in two patients. Trans Am Neurol Assoc 1976, 101:81–82.
45. Kerr DA, Chang CF, Gordon J, et al.: Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology 1993, 196(2):612–618.
46. Vollmer-Haase J, Young P, Ringelstein EB: Efficacy of camptothecin in progressive multifocal leucoencephalopathy [letter]. Lancet 1997, 349(9062):1366.
47. O’Reilly S: Efficacy of camptothecin in progressive multifocal leucoencephalopathy [letter]. Lancet 1997, 350(9073):291.
48. Power C, Nath A, Aoki FY, Bigio MD: Remission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection [letter]. N Engl J Med 1997, 336(9):661–662.
49. Conway B, Halliday WC, Brunham RC: Human immunodeficiency virus-associated progressive multifocal leukoencephalopathy: apparent response to 3¢-azido-3¢-deoxythymidine. Rev Infect Dis 1990, 12(3):479–482.
50. Inui K, Miyagawa H, Sashihara J, et al.: Remission of progressive multifocal leukoencephalopathy following highly active antiretroviral therapy in a patient with HIV infection. Brain Dev 1999, 21(6):416–419.
51. Tantisiriwat W, Tebas P, Clifford DB, et al.: Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 1999, 28(5):1152–1154.
52. Ledergerber B, Egger M, Erard V, et al.: AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999, 282(23):2220–2226.
53. Gasnault J, Taoufik Y, Goujard C, et al.: Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J Neurovirol 1999, 5(4):421–429.
54. De Luca A, Ammassari A, Cingolani A, et al.: Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretroviral therapy [letter]. AIDS 1998, 12(14):1937–1938.